Alpha7 PAMs for neurodegeneration therapy

Overview

Alpha7 potentiators, also known as positive allosteric modulators (PAMs), are emerging as promising therapeutic candidates for neurodegenerative diseases. These compounds offer a multifaceted approach by targeting key pathological mechanisms such as neuroinflammation, neuronal protection, and the prevention of pathogenic protein aggregation. By modulating the alpha7 nicotinic acetylcholine receptors, these PAMs can improve cognitive function, protect neuronal integrity, and inhibit aggregation of proteins like alpha-synuclein and beta-amyloid, which are crucial in conditions like Alzheimer's and Parkinson's diseases.

Technical specifications

Key features:

• Anti-inflammatory properties: Reduces neuroinflammation and microglial activation.
• Neuroprotective effects: Protects neuronal cells and improves cognitive function.
• Antiaggregant activity: Prevents aggregation of pathogenic proteins such as beta-amyloid and alpha-synuclein.
• Electrophysiological validation: Potentiation of alpha7 is measured through electrophysiological recordings and calcium measurements.
• ADMET optimization: Compounds are selected based on favorable absorption, distribution, metabolism, excretion, and toxicity profiles.
• Disease model efficacy: Compounds are validated in C. elegans models for reversing phenotypes of neurodegenerative diseases.

Technology readiness level

Currently at TRL 2, this research is in the stage of experimental proof of concept. The project involves computational screening to identify potential compounds, followed by rigorous in vitro and in vivo validation processes to assess their efficacy and safety. This sequential approach aims to refine and identify the most promising alpha7 PAM candidates for further development.